Spruce Biosciences Inc. (SPRB) that reached significant study milestones last year, anticipates a year filled with key catalysts in 2024.
This clinical-stage biopharmaceutical company is developing novel therapies for rare endocrine disorders with significant unmet medical need. The lead drug candidate is Tildacerfont, being developed for patients with classic congenital adrenal hyperplasia (CAH) and other diseases characterized by elevated levels of adrenocorticotropic hormone (ACTH).
For comments and feedback contact: editorial@rttnews.com
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.